Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry.
Financial Results:
Suven Pharmaceuticals Ltd reported Revenues for Q2FY24 of ₹231.00 Crores down from ₹278.00 Crore year on year, a fall of 16.91%.
Total Expenses for Q2FY24 of ₹145.00 Crores down from ₹191.00 Crores year on year, a fall of 24.08%.
Consolidated Net Profit of ₹80.00 Crores up 11.11% from ₹72.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹3.13, up 10.60% from ₹2.83 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.